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To the Editor: 
Familial occurrence of mastocytosis is unusual. Most of the clustered cases 
were pediatric cutaneous mastocytosis without KIT mutations, or presenting 
uncommon KIT lesions, not yet reported in sporadic cases (ie, A533D or K509I 
point mutation or deletion of exons 418 and 559-560, in association with familial 
gastrointestinal stromal tumors). These data suggest that familial mastocytosis 
comprises a subgroup with a different pathogenesis from the sporadic 
mastocytosis that is typically associated with the D816V KIT mutation. Here, we 
report a case of familial systemic mastocytosis (SM) without skin lesions 
presented in 2 adults, a mother and her son, both carrying the D816V mutation, 
and associated with systemic reaction to hymenoptera venom. Patients 1 and 2 
had no personal or familial history of skin disorders, hematological diseases, 
gastrointestinal stromal tumor, or other cancer. The unique sister of patient 1 
had normal serum tryptase levels and refused any other evaluation. Patient 1 
(male, aged 32 years) came to the Allergy Service of Feltre, Belluno (Italy), in 
2002 after a systemic reaction (Mueller III) subsequent to a hymenoptera sting, 
identified as a vespula. Skin prick tests and intradermal tests to Apis mellifera 
(I1), Vespa crabro (I75), Polistes dominulus (I77), Vespula species (I3), and 
Bombus terrestris were performed according to the recommendations of the 
European Academy of Allergology and Clinical Immunology; they evidenced 
positivity for the I3 venom, which was further confirmed by detection of specific 
IgE serum antibodies (CAP test, Pharmacia, Uppsala, Sweden). In July 2002, 
the patient started specific immunotherapy to Vespula species, which is still in 
course. From 2005 to 2009, he was sometimes stung by a vespid without any 
reaction. In 2006, a Bombus species field sting caused a Muller IV grade 
systemic reaction that determined his admission to the emergency room. Skin 
prick test and detection of specific serum IgE were repeated, and the tests 
confirmed a sensitization only to Vespula species. Furthermore, serum tryptase 
level was 12.5ng/mL and he did not show any other mediator-related associated 
symptoms. Patient 2 (female, 57 years, mother of patient had a history of 
osteoporosis, which was treated with alendronate 70 mg once a week. In 2002, 
she was stung by a vespid and had Muller I systemic reaction. Skin prick test 
and detection of specific IgE serum antibodies were positive for I3 and I4 
(Polistes species).  
Vespula venom specific immunotherapy was started, but the patient suffered 
from Muller I systemic reaction after the dose of 20 mg. After a week, the serum 
tryptase level was 42ng/mL. Some weeks later, she restarted the 
immunotherapy without any problems. She did not show any other mediator-
related symptoms. The history of systemic reactions after hymenoptera sting 
and persistent raised tryptase serum levels led to the suspicion of SM. Both 
patients were referred to the Multidisciplinary Outpatients Clinic for 
Mastocytosis of Verona, Italy, where they underwent physical examination, 
complete blood cell count, routine biochemistry, abdominal ultrasonography, 
bone densitometry evaluation with dual-energy x-ray absorptiometry, and bone 
marrow evaluation with histology/cytology and flow cytometric analysis, 
performed as previously described. The D816V KIT mutation was demonstrated 
in both patients on total RNA from bone marrow samples by real-time PCR 
using mismatched forward primers for both mutated and wild-type sequence to 
control cDNA quality and by peptide nucleic acidmediated PCR clamping and 
hybridization probes (the analyses were performed independently in Verona 
and Salamanca Laboratories). The presence of the D816V mutation was also 
investigated on genomic DNA from total peripheral blood (PB) and from 
fluorescence-activated cell sorting–purified populations of PB neutrophils, 
monocytes, and lymphocytes, by allelespecific real-time quantitative PCR. 
Genomic DNA from total PB sample of the son showed a slight positivity (2.5%-
5%) of the D816V KIT mutation, whereas the mother was negative, which would 
confirm that it was not a case of germline but somatic mutation. Moreover, 
analysis of genomic DNA from purified PB cell populations of the son revealed 
that only monocytes and granulocytes carried the D816V KIT mutation while T 
lymphocytes were negative for this mutation. Clinical, laboratory, and bone 
marrow characteristics are reported in Table I. Both patients were diagnosed 
with indolent SM without skin lesions on the basis of 3 minor criteria (patient 1) 
or 1 major criteria and 4 minor criteria (patient 2) according to the current World 
Health Organization recommendations. To the best of our knowledge, this is the 
first report of a family (mother and son) with adult-onset SM associated with the 
occurrence of somatic D816V KIT mutation on both patients. Given the rarity of 
this disease, the simultaneous occurrence on both patients of the D816V KIT 
mutation by chance is negligible; therefore, SM onset is due to some type of 
parental inheritance. Nevertheless, the D816V mutation was somatic but not 
germline, as it has been shown to be restricted to a small part of the myeloid 
compartment of hematopoiesis. It is generally accepted that unlike familial 
mastocytosis, adult patients with sporadic mastocytosis usually express 
activating mutations in exon 17 of KIT, most commonly D816V,2 and this 
mutation has never been shown to be inherited.1 Indeed, a study performed on 
50 pediatric cases showed that despite 36% of the cases being positive for the 
D816V KIT mutation, they were always somatic, including 2 brothers with a 
familial form of the disease without any history of KIT-related tumors (other than 
mastocytosis).  
The latter observation is consistent with a case of adult-onset familial SM in 
monozygotic twins with skin lesions and somatic D816V mutation. Therefore, 
the report of somatic D816V KIT mutation in familial cases of mastocytosis 
(either with children or adult onset) suggests the presence of other genetic 
factors predisposing to the acquisition of somatic-activating KIT mutation. 
Despite the fact that a great number of growth factor signal transduction 
pathways are closely related to KIT transduction pathways and may influence 
mast cell proliferation and survival (reviewed in Orfao et al ), and polymorphism 
of genes encoding for mast cell growth factors and their receptors (eg, IL-13 
and IL-4R) is described to influence different phenotypes in mastocytosis, to the 
best of our knowledge there is still not enough scientific evidence to assume 
any potential genetic candidate predisposing the development of mastocytosis. 
 
 
 
 
TABLE I. Clinical, laboratory, BM, and PB characteristics of 2 patients at diagnostic of 
SM 
                                                                        Patient 1                                  Patient 2 
Sex                                                                     Male                                        Female 
Age (y)                                                                 37                                               57 
Hemoglobin, median (gr/dL)                               16.1                                            14.2 
White cell count, median (X109/L)                      5.3                                               7.0 
Platelet count, median (X109/L)                         195                                             212 
Tryptase level (ng/mL)                                       12.4                                              42.0 
Skin lesions                                                        Absent                                       Absent 
Hepatosplenomegaly                                         Absent                                       Absent 
Lymphadenopathy                                             Absent                                        Absent 
BM histology 
Cellularity (%)                                                       40                                                  60 
Multifocal, dense MC aggregates                     Negative*                                Positive 
BM cytology 
% of atypical type I MC within all 
nucleated BM cells                                                 <1                                                   <1 
(% of BM atypical MC type I of all 
BM MCs)                                                                 75                                                85 
BM flow cytometry 
% of CD251 BM MCs within 
nucleated BM cells                                                  0.33                                              
0.43 
D816V on BM cDNA                                            Positive                                  Positive 
D816V on PB gDNA                                            Positive (2.5%-5%)                 Negative 
D816V on monocytes gDNA                                Positive                                     – 
D816V on granulocytes gDNA                             Positive                                      – 
D816V on T-lymphocytes gDNA                           Negative                                    – 
 
BM, Bone marrow; gDNA, genomic DNA; MC, mast cell. 
*Small aggregates of atypical MCs. 
 
 
  
 
 
 
 
 
